TNF Pharmaceuticals, Inc. (TNFA) - Total Assets
Based on the latest financial reports, TNF Pharmaceuticals, Inc. (TNFA) holds total assets worth $17.15 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check TNF Pharmaceuticals, Inc. investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
TNF Pharmaceuticals, Inc. - Total Assets Trend (2004–2024)
This chart illustrates how TNF Pharmaceuticals, Inc.'s total assets have evolved over time, based on quarterly financial data. Explore TNFA long-term investment intensity to see how much of total assets are deployed in long-term investments.
TNF Pharmaceuticals, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
TNF Pharmaceuticals, Inc.'s total assets of $17.15 Million consist of 43.9% current assets and 56.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $10.50 Million | 49.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how TNF Pharmaceuticals, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TNFA market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TNF Pharmaceuticals, Inc.'s current assets represent 43.9% of total assets in 2024, a decrease from 75.9% in 2004.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, down from 12.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 7.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 49.0% of total assets.
TNF Pharmaceuticals, Inc. Competitors by Total Assets
Key competitors of TNF Pharmaceuticals, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
TNF Pharmaceuticals, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 2.48 | 0.02 |
| Quick Ratio | 0.93 | 2.48 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-397.58K | $8.57 Million | $-2.73 Million |
TNF Pharmaceuticals, Inc. - Advanced Valuation Insights
This section examines the relationship between TNF Pharmaceuticals, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.84 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | 19.9% |
| Total Assets | $21.42 Million |
| Market Capitalization | $6.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values TNF Pharmaceuticals, Inc.'s assets below their book value (0.32x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: TNF Pharmaceuticals, Inc.'s assets grew by 19.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TNF Pharmaceuticals, Inc. (2004–2024)
The table below shows the annual total assets of TNF Pharmaceuticals, Inc. from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $21.42 Million | +19.92% |
| 2023-12-31 | $17.86 Million | +1.84% |
| 2022-12-31 | $17.54 Million | -29.31% |
| 2021-12-31 | $24.81 Million | -32.65% |
| 2020-12-31 | $36.84 Million | +238.47% |
| 2019-12-31 | $10.88 Million | +39.42% |
| 2018-12-31 | $7.81 Million | -16.39% |
| 2017-12-31 | $9.34 Million | +83.63% |
| 2016-12-31 | $5.09 Million | -38.53% |
| 2015-12-31 | $8.27 Million | -50.32% |
| 2014-12-31 | $16.65 Million | +174.06% |
| 2013-12-31 | $6.08 Million | -5.32% |
| 2012-12-31 | $6.42 Million | -6.77% |
| 2011-12-31 | $6.88 Million | -10.80% |
| 2010-12-31 | $7.72 Million | -7.34% |
| 2009-12-31 | $8.33 Million | -26.13% |
| 2008-12-31 | $11.27 Million | +59.79% |
| 2007-12-31 | $7.06 Million | +134.96% |
| 2006-12-31 | $3.00 Million | -63.53% |
| 2005-12-31 | $8.24 Million | +455.70% |
| 2004-12-31 | $1.48 Million | -- |
About TNF Pharmaceuticals, Inc.
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rh… Read more